{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-023698","form_type":"8-K","ticker":"DMAC","cik":"0001401040","company_name":"DiaMedica Therapeutics Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.791996+00:00","generated_at":"2026-06-11T10:32:23.734997+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"DiaMedica Therapeutics Q2 2023: clinical hold lifted, $37.5M private placement, cash $60.7M","bullets":["FDA fully lifted clinical hold on ReMEDy2 Phase 2/3 trial of DM199 for acute ischemic stroke on June 21, 2023.","Completed $37.5M private placement (~11M shares at $3.40; net proceeds ~$36.1M); cash runway into 2026.","Cash, cash equivalents and investments of $60.7M as of June 30, 2023, up from $33.5M at Dec 31, 2022.","R&D expenses increased to $6.2M for H1 2023 (up from $3.9M) due to clinical hold resolution and Phase 1C study.","Phase 1C study in ACEi patients completed; all received full IV dose with no hypotension."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-023698","json":"https://secwatch.observer/filing/0001437749-23-023698.json","markdown":"https://secwatch.observer/filing/0001437749-23-023698.md","text":"https://secwatch.observer/filing/0001437749-23-023698.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401040/000143774923023698/0001437749-23-023698-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401040/000143774923023698/dmtp20230814_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T10:32:23.734997+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}